Traditional Roles in a Non‐Traditional Setting: Genetic Counseling in Precision Oncology. Issue 4 (1st March 2014)

• Record Type: Journal Article
• Authors: Everett, Jessica N.; Gustafson, Shanna L.; Raymond, Victoria M.
• Is Part Of: Journal of genetic counseling. Volume 23:Issue 4(2014)
• Page Start: 655
• Page End: 660
• Publication Date: 2014-03-01
• Subjects: Genetic counseling -- Whole genome sequencing -- Precision oncology; Genetic counseling -- Periodicals; 616.042
• DOI: 10.1007/s10897-014-9698-3
• Languages: English
• ISSNs: 1059-7700

Abstract

Abstract: Next generation sequencing technology is increasingly utilized in oncology with the goal of targeting therapeutics to improve response and reduce side effects. Interpretation of tumor mutations requires sequencing of paired germline DNA, raising questions about incidental germline findings. We describe our experiences as part of a research team implementing a protocol for whole genome sequencing (WGS) of tumors and paired germline DNA known as the Michigan Oncology Sequencing project (MI‐ONCOSEQ) that includes options for receiving incidental germline findings. Genetic counselors (GCs) discuss options for return of results with patients during the informed consent process and document family histories. GCs also review germline findings and actively participate in the multi‐disciplinary Precision Medicine Tumor Board (PMTB), providing clinical context for interpretation of germline results and making recommendations about disclosure of germline findings. GCs have encountered ethical and counseling challenges with participants, described here. Although GCs have not been traditionally involved in molecular testing of tumors, our experiences with MI‐ONCOSEQ demonstrate that GCs have important applicable skills to contribute to multi‐disciplinary care teams implementing precision oncology. Broader use of WGS in oncology treatment decision making and American College of Medical Genetics and Genomics (ACMG) recommendations for active interrogation of germline tissue in tumor‐normal dyads suggests that GCs will have future opportunities in this area outside of research settings.